TrialPath
Recruiting

Insulin Resistance in Multiple System Atrophy

NCT04250493 · University Hospital, Bordeaux
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
Multiple system atrophy (MSA) patients have a poor prognosis with a median survival ranging between 6 and 10 years. MSA belongs to the synucleinopathies, which are characterized by the abnormal accumulation of alpha-synuclein. We have recently shown brain insulin resistance (i.e. reduced insulin signaling) in post-mortem brain tissue of MSA patients and transgenic MSA mice, as illustrated by increased protein levels of insulin receptor substrate-1 phosphorylated at serine 312 (IRS-1pS312). Additionally, exendin-4, an approved anti-diabetic drug targeting glucagon-like peptide-1 (GLP-1) receptors, was capable of decreasing brain levels of IRS-1pS312 and preserving dopamine neurons in transgenic MSA mice. We further observed an inverse correlation between plasma neural-derived exosomal IRS-1pS312 levels and survival of dopamine neurons in transgenic MSA mice. The aim of this study is to further characterize peripheral and central insulin resistance in MSA patients, thereby validating this target for future treatment trials. For this purpose, fasting blood glucose and insulin levels will be determined in samples of MSA patients and healthy controls for a homeostatic model assessment of insulin resistance (HOMA). Additionally, IRS-1pS312 will be measured in neural-derived plasma exosomes of MSA patients and healthy controls.
Eligibility criteria
Inclusion Criteria: Patients : * Patients suffering from "possible" or "probable" MSA according to clinical consensus criteria (Gilman et al., 2008). * Age \> 30 * Written informed consent * Patient covered by the national health system Controls: * Patients not suffering from a neurologic disorder * Age \> 30 * Written informed consent * Patient covered by the national health system Exclusion Criteria: For patients and controls: * Presence of a diabetes * Treatment with corticosteroids, estrogen, atypical antipsychotics, and anti-retroviral agents * Patient under tutelage * Patient unable to give consent * Any other neurologic disorder * Pregnancy and breastfeeding * MOCA ≤21 * Contraindication to perform an MRI
Study design
Enrollment target: 124 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2020-10-28
Estimated completion: 2027-10-28
Last updated: 2025-07-20
Interventions
Biological: Homeostasis Model Assessment of insulin resistance (HOMA)Behavioral: MOntreal Cognitive Assessment (MoCA)Behavioral: Clinical characteristics of AMS patientsProcedure: Brain Magnetic Resonance Imaging (MRI)Biological: Blood sampling
Primary outcomes
  • • HOMA Index (Day 0)
Sponsor
University Hospital, Bordeaux · other
With: University of Bordeaux, Labex Brain, Centre National de la Recherche Scientifique, France
Contacts & investigators
ContactWassilios MEISSNER · contact · wassilios.meissner@chu-bordeaux.fr · 05 57 82 14 20
All locations (1)
CHU de BordeauxRecruiting
Bordeaux, France